{"id":139358,"date":"2026-07-03T13:24:12","date_gmt":"2026-07-03T07:54:12","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=139358"},"modified":"2026-07-03T13:24:13","modified_gmt":"2026-07-03T07:54:13","slug":"zydus-lifesciences-share-price-apollo-hospitals-mou-shield-test","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-share-price-apollo-hospitals-mou-shield-test\/","title":{"rendered":"Zydus Lifesciences Share Price Hits 52-Week High on Apollo Hospitals MoU for Shield Cancer Test"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>Zydus Lifesciences Rs 1,134 (+3.12%), fresh 52-week high. MoU with Apollo Hospitals to offer Guardant Health&#8217;s Shield Multi-Cancer Detection test in India.<\/em><\/p>\n<p><a href=\"https:\/\/univest.in\/user\/stocks\/zyduslife\/zydus-lifesciences-ltd-share-price-today\">Zydus Lifesciences<\/a> share price surged 3.12 percent to touch a fresh 52-week high of Rs 1,134 on Thursday after the company signed a memorandum of understanding with Apollo Hospitals to offer the Shield Multi-Cancer Detection test in India, extending an exclusive partnership with US based Guardant Health.<\/p>\n<p>Under the exclusive agreement behind today&#8217;s move in Zydus Lifesciences share price, Zydus Lifesciences and Guardant Health will make the Shield test available in India, with Apollo Hospitals now onboarded as a key partner to offer the multi-cancer early detection screening across its hospital network.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=zydus-lifesciences-apollo-hospitals-mou-shield-test\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-share-price-apollo-hospitals-mou-shield-test\/#Zydus_Lifesciences_Key_Metrics\" title=\"Zydus Lifesciences Key Metrics\">Zydus Lifesciences Key Metrics<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-share-price-apollo-hospitals-mou-shield-test\/#What_the_Shield_Test_Partnership_Means_for_Zydus_Lifesciences_Share_Price\" title=\"What the Shield Test Partnership Means for Zydus Lifesciences Share Price\">What the Shield Test Partnership Means for Zydus Lifesciences Share Price<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-share-price-apollo-hospitals-mou-shield-test\/#Outlook_for_Zydus_Lifesciences_Share_Price\" title=\"Outlook for Zydus Lifesciences Share Price\">Outlook for Zydus Lifesciences Share Price<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-share-price-apollo-hospitals-mou-shield-test\/#Key_Risks_to_Watch_on_Zydus_Lifesciences_Share_Price\" title=\"Key Risks to Watch on Zydus Lifesciences Share Price\">Key Risks to Watch on Zydus Lifesciences Share Price<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-share-price-apollo-hospitals-mou-shield-test\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-share-price-apollo-hospitals-mou-shield-test\/#FAQs_on_Zydus_Lifesciences_Share_Price\" title=\"FAQs on Zydus Lifesciences Share Price\">FAQs on Zydus Lifesciences Share Price<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-share-price-apollo-hospitals-mou-shield-test\/#1_Why_did_Zydus_Lifesciences_share_price_hit_a_52-week_high_today\" title=\"1. Why did Zydus Lifesciences share price hit a 52-week high today?\">1. Why did Zydus Lifesciences share price hit a 52-week high today?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-share-price-apollo-hospitals-mou-shield-test\/#2_What_is_the_Shield_test\" title=\"2. What is the Shield test?\">2. What is the Shield test?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-share-price-apollo-hospitals-mou-shield-test\/#3_What_is_the_Apollo_Hospitals_partnership_about\" title=\"3. What is the Apollo Hospitals partnership about?\">3. What is the Apollo Hospitals partnership about?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-share-price-apollo-hospitals-mou-shield-test\/#4_What_is_Zydus_Lifesciences_52-week_high\" title=\"4. What is Zydus Lifesciences&#8217; 52-week high?\">4. What is Zydus Lifesciences&#8217; 52-week high?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-share-price-apollo-hospitals-mou-shield-test\/#5_Who_is_Guardant_Health\" title=\"5. Who is Guardant Health?\">5. Who is Guardant Health?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-share-price-apollo-hospitals-mou-shield-test\/#6_What_are_the_key_risks_to_Zydus_Lifesciences_share_price\" title=\"6. What are the key risks to Zydus Lifesciences share price?\">6. What are the key risks to Zydus Lifesciences share price?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Zydus_Lifesciences_Key_Metrics\"><\/span><strong>Zydus Lifesciences Key Metrics<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table border=\"1\" cellspacing=\"0\" cellpadding=\"6\">\n<tbody>\n<tr>\n<th>Metric<\/th>\n<th>Value<\/th>\n<\/tr>\n<tr>\n<td>CMP<\/td>\n<td>Rs 1,134.00<\/td>\n<\/tr>\n<tr>\n<td>Day Change<\/td>\n<td>+3.12%<\/td>\n<\/tr>\n<tr>\n<td>52 Week High<\/td>\n<td>Rs 1,129.85 (fresh high touched today)<\/td>\n<\/tr>\n<tr>\n<td>Intraday High<\/td>\n<td>Rs 1,129.85<\/td>\n<\/tr>\n<tr>\n<td>Intraday Low<\/td>\n<td>Rs 1,103.80<\/td>\n<\/tr>\n<tr>\n<td>Volume Change<\/td>\n<td>+17.65% vs 5-day average<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check the Univest Screener for Live Pharma Sector Data<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_the_Shield_Test_Partnership_Means_for_Zydus_Lifesciences_Share_Price\"><\/span><strong>What the Shield Test Partnership Means for Zydus Lifesciences Share Price<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><a href=\"https:\/\/univest.in\/stocks\/zyduslife\/zydus-lifesciences-ltd-share-price-today\">Zydus Lifesciences<\/a>, one of India&#8217;s leading pharmaceutical and healthcare companies, has been expanding into the diagnostics and early cancer detection space through its exclusive tie-up with Guardant Health, a US based precision oncology company known for its blood based multi-cancer detection technology. The Shield test is designed to screen for multiple cancer types through a simple blood draw, a technology that has gained attention globally for its potential to improve early cancer detection rates. This is a key data point for anyone tracking the Zydus Lifesciences share price today.<\/p>\n<p>The MoU with Apollo Hospitals gives Zydus Lifesciences access to one of India&#8217;s largest hospital networks to distribute and offer the Shield test, a distribution partnership that could meaningfully expand the reach of this diagnostic offering across the country, supporting the positive sentiment reflected in today&#8217;s Zydus Lifesciences share price move.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Outlook_for_Zydus_Lifesciences_Share_Price\"><\/span><strong>Outlook for Zydus Lifesciences Share Price<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>With India&#8217;s cancer diagnostics and early screening market still in a relatively nascent stage of adoption compared to developed markets, Zydus Lifesciences&#8217; positioning with an exclusive, technologically differentiated product like the Shield test could provide a meaningful growth avenue beyond its core pharmaceutical business. The pace of rollout across Apollo Hospitals&#8217; network and the test&#8217;s pricing and adoption rates will be key factors determining how much this partnership contributes to Zydus Lifesciences&#8217; revenue over the coming quarters. Investors watching the Zydus Lifesciences share price should note this development closely.<\/p>\n<p><em>Quick take: today&#8217;s rally in Zydus Lifesciences share price to a fresh 52-week high reflects investor enthusiasm for the company&#8217;s expansion into differentiated cancer diagnostics, though the commercial scale of this opportunity will become clearer as the Shield test rolls out across Apollo&#8217;s network.<\/em><\/p>\n<p style=\"margin-top: 24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Zydus Lifesciences&#8217; live price and updates.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_Watch_on_Zydus_Lifesciences_Share_Price\"><\/span><strong>Key Risks to Watch on Zydus Lifesciences Share Price<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>As a newer diagnostic offering in the Indian market, the commercial success of the Shield test will depend on pricing, insurance coverage and patient awareness, factors that could take time to develop fully. Investors should also note that Zydus Lifesciences share price is now trading at a fresh 52-week high, a level that can sometimes see profit booking once the initial enthusiasm around a specific announcement fades.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Zydus Lifesciences share price touched a fresh 52-week high today after the company signed an MoU with Apollo Hospitals to offer the Shield Multi-Cancer Detection test in India, extending its exclusive partnership with Guardant Health into a major hospital distribution channel. Investors should track the pace of rollout and adoption of this diagnostic offering as the key factor determining its longer term contribution to the company&#8217;s growth. This article is for educational purposes and is not investment advice; consult a SEBI-registered investment adviser before making any investment decision.<\/p>\n<div style=\"background: #CC0000; border-radius: 8px; padding: 16px 20px; margin: 24px 0;\">\n<p style=\"color: #ffffff; font-size: 13px; line-height: 1.7; margin: 0;\"><strong style=\"color: #ffffff;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"FAQs_on_Zydus_Lifesciences_Share_Price\"><\/span><strong>FAQs on Zydus Lifesciences Share Price<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"1_Why_did_Zydus_Lifesciences_share_price_hit_a_52-week_high_today\"><\/span><strong>1. Why did Zydus Lifesciences share price hit a 52-week high today?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The stock rallied after Zydus Lifesciences signed an MoU with Apollo Hospitals to offer the Shield Multi-Cancer Detection test in India, extending its exclusive partnership with Guardant Health.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"2_What_is_the_Shield_test\"><\/span><strong>2. What is the Shield test?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Shield Multi-Cancer Detection test, developed by Guardant Health, is a blood based diagnostic designed to screen for multiple cancer types through early detection technology.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"3_What_is_the_Apollo_Hospitals_partnership_about\"><\/span><strong>3. What is the Apollo Hospitals partnership about?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Zydus Lifesciences signed an MoU with Apollo Hospitals to distribute and offer the Shield test across Apollo&#8217;s hospital network in India.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"4_What_is_Zydus_Lifesciences_52-week_high\"><\/span><strong>4. What is Zydus Lifesciences&#8217; 52-week high?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The stock touched a fresh 52-week high of Rs 1,129.85 during today&#8217;s session.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"5_Who_is_Guardant_Health\"><\/span><strong>5. Who is Guardant Health?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Guardant Health is a US based precision oncology company known for its blood based multi-cancer detection technology, with which Zydus Lifesciences has an exclusive agreement for the Indian market.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"6_What_are_the_key_risks_to_Zydus_Lifesciences_share_price\"><\/span><strong>6. What are the key risks to Zydus Lifesciences share price?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The commercial success of the Shield test depends on pricing, insurance coverage and patient awareness, and the stock could see profit booking after reaching a fresh 52-week high.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"Why did Zydus Lifesciences share price hit a 52-week high today?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The stock rallied after Zydus Lifesciences signed an MoU with Apollo Hospitals to offer the Shield Multi-Cancer Detection test in India, extending its exclusive partnership with Guardant Health.\"}},{\"@type\":\"Question\",\"name\":\"What is the Shield test?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The Shield Multi-Cancer Detection test, developed by Guardant Health, is a blood based diagnostic designed to screen for multiple cancer types through early detection technology.\"}},{\"@type\":\"Question\",\"name\":\"What is the Apollo Hospitals partnership about?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Zydus Lifesciences signed an MoU with Apollo Hospitals to distribute and offer the Shield test across Apollo's hospital network in India.\"}},{\"@type\":\"Question\",\"name\":\"What is Zydus Lifesciences' 52-week high?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The stock touched a fresh 52-week high of Rs 1,129.85 during today's session.\"}},{\"@type\":\"Question\",\"name\":\"Who is Guardant Health?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Guardant Health is a US based precision oncology company known for its blood based multi-cancer detection technology, with which Zydus Lifesciences has an exclusive agreement for the Indian market.\"}},{\"@type\":\"Question\",\"name\":\"What are the key risks to Zydus Lifesciences share price?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The commercial success of the Shield test depends on pricing, insurance coverage and patient awareness, and the stock could see profit booking after reaching a fresh 52-week high.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Zydus Lifesciences share price hit a 52-week high after signing an MoU with Apollo Hospitals for the Shield Multi-Cancer Detection test. Details here.<\/p>\n","protected":false},"author":35,"featured_media":139408,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[],"class_list":["post-139358","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_edit_lock":["1783065257:26"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["76"],"rank_math_focus_keyword":["Zydus Lifesciences Share Price"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"rank_math_title":["Zydus Lifesciences Share Price Hits 52-Week High on Apollo MoU"],"rank_math_description":["Zydus Lifesciences share price hit a 52-week high after signing an MoU with Apollo Hospitals for the Shield Multi-Cancer Detection test. Details here."],"_thumbnail_id":["139408"],"_edit_last":["26"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["23272"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/07\/Zydus-Lifesciences-Share-Price-Hits-52-Week-High.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/139358","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/35"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=139358"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/139358\/revisions"}],"predecessor-version":[{"id":139409,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/139358\/revisions\/139409"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/139408"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=139358"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=139358"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=139358"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}